Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Nephros develops hemodiafiltration (HDF) products for End Stage Renal Disease (ESRD) and water filtration systems. Key products include the OLpur MDHDF filter series (sold in Europe/Canada), the OLpur H2H module (FDA review pending), and the Dual Stage Ultrafilter (DSU) water filtration system (FDA approved for dialysis water in July 2009). The company relies on contract manufacturers and holds significant government research contracts with the U.S. Department of Defense.
Key Financial Metrics
| Metric (in thousands) | 2009 | 2008 |
|---|---|---|
| Product Revenue | $2,661 | $1,473 |
| Gross Margin | $917 (34.5%) | $409 (27.8%) |
| Net Loss | $(2,026) | $(6,337) |
| Cash and Cash Equivalents | $1,004 | $2,306 |
| Accumulated Deficit | $(89,975) | $(87,949) |
| Net Cash Used in Operating Activities | $(2,612) | $(5,725) |
| Net Cash Provided by Financing Activities | $1,336 | $0 |
Debt and Liquidity: The company had no outstanding debt as of December 31, 2009. Total current liabilities were $694,000. Management estimates cash on hand ($1.0 million) would sustain operations only through June 2010.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 81% to $2.66 million, driven primarily by $1.09 million in revenue from Office of Naval Research (ONR) military contracts. European dialyzer sales increased slightly in volume but were negatively impacted by Euro-to-USD currency translation.
- Profitability Improvement: Net loss decreased significantly from $6.34 million in 2008 to $2.03 million in 2009. This was largely due to an 86% reduction in R&D expenses (no clinical trials in 2009 vs. 2008) and a 40% reduction in SG&A expenses.
- Investment Activity: In 2008, the company recorded a $114,000 impairment loss on Auction Rate Securities (ARS) followed by a realized gain upon sale. No ARS were held in 2009.
- Financing: In July 2009, the company raised $1.25 million via a private placement of common stock and warrants.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
Independent auditors have expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows. The company explicitly states it requires additional financing to fund operations beyond mid-2010.
Regulatory Status
- ESRD Products: The 510(k) application for the OLpur H2H module and MD220 filter remains under FDA review as of March 2010. No decision has been rendered.
- Water Filtration: The DSU received FDA approval in July 2009 for use in hemodialysis water purification.
Key Risks
- Customer Concentration: Two customers accounted for 87% of sales in 2009. One customer alone represented 46% of sales and 44% of accounts receivable.
- Supply Chain: The exclusive fiber supplier notified the company in January 2010 of its intent to terminate the supply agreement effective July 2010. Negotiations for a new agreement were ongoing.
- Management Turnover: The President and CEO, Ernest Elgin III, resigned on March 30, 2010. A separation and consulting agreement was executed.
- Delisting: The company was delisted from the AMEX in January 2009 and trades on the OTC Bulletin Board.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure financing before June 2010 to avoid cessation of operations.
- FDA Approval Timeline: Confirm the status of the pending 510(k) application for the H2H module and MD220 filter, which is critical for U.S. market entry.
- Supply Agreement: Monitor the outcome of negotiations with the fiber supplier to ensure continuity of European product manufacturing.
- Customer Dependency: Assess the risk associated with the loss of the single customer representing 46% of revenue.
- Management Stability: Evaluate the impact of the CEO resignation and the transition to the acting CEO.